---
input_text: 'Switching from zonisamide to perampanel improved the frequency of seizures
  caused by hyperthermia in Dravet syndrome: a case report. BACKGROUND: Dravet syndrome
  is a severe epilepsy disorder characterized by drug-resistant seizures and cognitive
  dysfunction, often caused by SCN1A gene mutations. It leads to neurodevelopmental
  delays and motor, behavioral, and cognitive impairments, with a high mortality rate.
  Treatment options include sodium valproate, clobazam, and newer agents such as cannabidiol
  and fenfluramine. Zonisamide, which is used in some cases, can cause hyperthermia
  and oligohydrosis. Herein, we present a case of a patient with Dravet syndrome whose
  seizures were controlled by treating infections and switching from zonisamide to
  perampanel. CASE PRESENTATION: A 24-year-old Japanese man with Dravet syndrome presented
  to our department with aspiration pneumonia. The patient had been treated with valproate,
  sodium bromide, and zonisamide for a long time. His seizures were triggered by hyperthermia.
  The patient was experiencing a sustained pattern of hyperthermia caused by infection,
  zonisamide, and persistent convulsions, which caused a vicious cycle of further
  seizures. In this case, the control of infection and switching from zonisamide to
  perampanel improved seizure frequency. CONCLUSION: Dravet syndrome usually begins
  with generalized clonic seizures in its infancy because of fever and progresses
  to various seizure types, often triggered by fever or seizure-induced heat due to
  mutations in the SCN1A gene that increases neuronal excitability. Seizures usually
  diminish with age, but the heat sensitivity remains. In this case, seizures were
  increased by repeated infections, and hyperthermia was induced by zonisamide, resulting
  in status epilepticus. Perampanel, an aminomethylphosphonic acid receptor antagonist,
  decreased seizures but caused psychiatric symptoms. It was effective in suppressing
  seizures of Dravet syndrome in this patient.'
raw_completion_output: |-
  primary_disease: Dravet syndrome

  medical_actions: Switching from zonisamide to perampanel; Treating infections; Use of sodium valproate; Use of clobazam; Use of cannabidiol; Use of fenfluramine

  symptoms: Seizures; Cognitive dysfunction; Neurodevelopmental delays; Motor impairments; Behavioral impairments; Cognitive impairments; Hyperthermia; Oligohydrosis; Aspiration pneumonia; Convulsions; Status epilepticus; Psychiatric symptoms

  chemicals: Zonisamide; Perampanel; Sodium valproate; Clobazam; Cannabidiol; Fenfluramine; Sodium bromide

  action_annotation_relationships: Switching from zonisamide to perampanel TREATS seizures IN Dravet syndrome; Treating infections TREATS hyperthermia IN Dravet syndrome; Use of sodium valproate TREATS seizures IN Dravet syndrome; Use of clobazam TREATS seizures IN Dravet syndrome; Use of cannabidiol TREATS seizures IN Dravet syndrome; Use of fenfluramine TREATS seizures IN Dravet syndrome; Zonisamide CAUSES hyperthermia IN Dravet syndrome; Perampanel TREATS seizures IN Dravet syndrome; Perampanel CAUSES psychiatric symptoms IN Dravet syndrome
prompt: |+
  Split the following piece of text into fields in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Perampanel CAUSES psychiatric symptoms IN Dravet syndrome

  ===

extracted_object:
  primary_disease: MONDO:0100135
  medical_actions:
    - Switching from zonisamide to perampanel
    - Treating infections
    - Use of sodium valproate
    - Use of clobazam
    - Use of cannabidiol
    - Use of fenfluramine
  symptoms:
    - HP:0001250
    - HP:0100543
    - HP:0012758
    - Motor impairments
    - Behavioral impairments
    - HP:0100543
    - HP:0001945
    - Oligohydrosis
    - HP:0011951
    - HP:0001250
    - HP:0002133
    - Psychiatric symptoms
  chemicals:
    - CHEBI:10127
    - CHEBI:71013
    - CHEBI:9925
    - CHEBI:31413
    - CHEBI:69478
    - CHEBI:5000
    - CHEBI:63004
  action_annotation_relationships:
    - subject: Switching from zonisamide to
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:71013
    - subject: Treating infections
      predicate: TREATS
      object: HP:0001945
      qualifier: MONDO:0100135
    - subject: Use of sodium valproate
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:9925
    - subject: Use of clobazam
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:31413
    - subject: Use of cannabidiol
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:69478
    - subject: Use of fenfluramine
      predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:5000
    - subject: Zonisamide
      predicate: CAUSES
      object: HP:0001945
      qualifier: MONDO:0100135
    - predicate: TREATS
      object: HP:0001250
      qualifier: MONDO:0100135
      subject_extension: CHEBI:71013
    - predicate: CAUSES
      object: psychiatric symptoms
      qualifier: MONDO:0100135
      subject_extension: CHEBI:71013
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
  - id: CHEBI:190616
    label: N-desmethylclobazam
  - id: MONDO:0013801
    label: SCN8A encephalopathy
  - id: HP:0001263
    label: Developmental delay
  - id: HP:0100543
    label: Cognitive impairment
  - id: CHEBI:35493
    label: antipyretics
  - id: MAXO:0000932
    label: Electroencephalography (EEG)
  - id: HP:0002353
    label: EEG abnormalities
  - id: CHEBI:73601
    label: <Ketogenic diet (KD)>
  - id: CHEBI:49575
    label: diazepam
  - id: CHEBI:6931
    label: midazolam
  - id: CHEBI:3756
    label: clonazepam
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0010083
    label: Succinic semialdehyde dehydrogenase deficiency
  - id: HP:0000739
    label: Anxiety
  - id: CHEBI:10127
    label: Zonisamide
  - id: CHEBI:87016
    label: Eslicarbazepine acetate
  - id: CHEBI:135939
    label: Lacosamide
  - id: MONDO:0700092
    label: Neurodevelopmental disorders (NDDs)
  - id: CHEBI:63631
    label: Topiramate
  - id: CHEBI:15858
    label: Bromides
  - id: MAXO:0000127
    label: Genetic testing
  - id: MONDO:0008297
    label: Vaccine proximate seizures (VPS)
  - id: MAXO:0000943
    label: deep brain stimulation (DBS)
  - id: MAXO:0000940
    label: responsive neurostimulation (RNS)
  - id: MONDO:0005071
    label: Neurological disorders
  - id: CHEBI:133053
    label: 7-OH-CBD
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: HP:0001873
    label: thrombocytopenia
  - id: CHEBI:8107
    label: Phenytoin
  - id: HP:0012758
    label: Neurodevelopmental delays
  - id: HP:0011951
    label: Aspiration pneumonia
  - id: CHEBI:71013
    label: Perampanel
  - id: CHEBI:63004
    label: Sodium bromide
